scholarly journals Inflammatory Markers: C-Reactive Protein, Erythrocyte Sedimentation Rate, and Leukocyte Count in Vitamin D Deficient Patients with and without Chronic Kidney Disease

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Ibrahim Yildirim ◽  
Ender Hur ◽  
Furuzan Kokturk
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Renal Failure ◽  
Kidney Disease ◽  
Vitamin B12 ◽  
Inflammatory Markers ◽  
Vitamin B12 Deficiency ◽  
Reactive Protein ◽  
25 Hydroxy Vitamin D ◽  
B12 Deficiency

Although some studies revealed a positive relationship between vitamin D3deficiency and inflammatory markers, there have been also many studies that failed to find this relationship. The aim of this large scaled study is to determine the association between the level of plasma 25 hydroxy vitamin D3[25-(OH) D3] and inflammatory markers in the general population without chronic kidney disease (CKD) and in patients with CKD. Participants with simultaneously measured inflammatory markers and 25-(OH) D3levels were retrospectively analyzed (n=1897). The incidence of all-cause inflammation infection, hospitalization, chronic renal failure, and vitamin B12 deficiency was evaluated. The medians of serum creatinine levels in subjects without renal failure were lower in 25-(OH) D3deficient group. Patients with CKD were more likely to have vitamin D3deficiency compared with normal GFR. 25-(OH) D3levels were associated with a greater incidence of all-cause hospitalization, hypoalbuminemia, and vitamin B12 deficiency. However, there was no relationship between inflammatory markers and vitamin D3levels. In 25-(OH) D3deficient patients, inflammatory markers can be related to other inflammatory and infectious status such as malnutrition and cachexia. We believed that there must be a relationship between vitamin deficiency and inflammatory markers due to other causes than low 25-(OH) D3status.

scholarly journals Study of vitamin B12 deficiency in chronic kidney disease

2020 ◽  
Vol 7 (2) ◽  
pp. 303
Author(s):  
Vinod Ananda Dandge ◽  
Dhruv Variya
Keyword(s):  
Chronic Kidney Disease ◽  
Folic Acid ◽  
Kidney Disease ◽  
Vitamin B12 ◽  
Serum Vitamin ◽  
Vitamin B12 Deficiency ◽  
Left Ventricular ◽  
Nutritional Deficiencies ◽  
Folic Acid Deficiency ◽  
B12 Deficiency

Background: Chronic Kidney Disease (CKD) is a growing health burden and important cause of morality and morbidity worldwide as well as India. Anaemia a feature of CKD, is multifactorial, one of the most important factor responsible for the development of left ventricular hypertrophy, diastolic and later systolic dysfunction and cardiovascular disease, which is the single most important contributor to the mortality in CKD. Severe Chronic Kidney Disease has an adverse effect on haematopoiesisis. Lack of erythropoietin, Iron deficiency anaemia and shortened red cell life span, Nutritional deficiency or deranged metabolism of vitamins is the major factors contributing to anaemia in CRF. Patients with CKD show megaloblastosis on examination of the bone marrow. Suggestive of Vitamin B12 and folic acid deficiency might Be Additional Factors Contributing to inadequate Haematopoiesis in uremia. Patients with CKD are at higher risk for nutritional deficiencies due to medication interactions, dietary restrictions and malnutrition. The dialysis procedure itself may cause loss of vitamin B12, Folic acid and there deficiency.Methods: Sample size of 80 cases of CKD patients aged between 18-80 year admitted in SMIMER Hospital were included in study. Serum vitamin B12 Level was checked, correlation B12 deficiency with duration of CKD was observed.Results: It was observed that, 47 cases of CKD had vitamin B12 deficiency. The mean duration of CKD is more in B12deficient group as compared to Normal Group and also finds the higher proportion of vitamin B12 deficiency in CKD patients.Conclusions: Serum vitamin B12 level testing should be recommended routinely in patients with CKD and All the treating Nephrologists should anticipate the deficiency of vitamin B12 in CKD patients.

scholarly journals Vitamin B12 Deficiency In Chronic Kidney Disease

2016 ◽  
Vol 15 (09) ◽  
pp. 22-25 ◽  
Author(s):  
Rohan G Patil ◽  
Deepak G Bhosle ◽  
Rizwan Abdul Hakim Malik
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Vitamin B12 ◽  
Vitamin B12 Deficiency ◽  
B12 Deficiency

scholarly journals The prevalence of low serum levels of Vitamin D, Vitamin B12, folate and ferritin in adolescents: Single center experience

2021 ◽  
Vol 104 (2) ◽  
pp. 003685042110076
Author(s):  
Nazmi Mutlu Karakaş
Keyword(s):  
Vitamin D ◽  
Vitamin B12 ◽  
Medical Records ◽  
Vitamin B12 Deficiency ◽  
Serum Levels ◽  
Folate Deficiency ◽  
Well Child Care ◽  
Single Center Experience ◽  
B12 Deficiency ◽  
Prevalence Of Anemia

Background: In this study, the aim was to evaluate the prevalence of vitamin D, vitamin B12, ferritin, and folate deficiencies in adolescence to clarify the need for early diagnosis and therapy. Methods: The medical records of adolescents between 10 and 18 years of age between 01 September 2018 and 28 February 2019 as healthy with non-specific complaints, or due to well-child care visits, were analyzed retrospectively. Results: A total of 1847/2507 (73.6%) adolescents were included in the study. The prevalence of vitamin D deficiency was 25.7% (n: 178/691). Vitamin B12 deficiency prevalence was 69.2% (n: 753/1088). The prevalence of anemia and ferritin deficiency was 4.8% and 13.26%. The prevalence of folate deficiency was 37.9% (n: 413/1088). VDD prevalence was statistically significantly higher in females than males (F/M:116/62). VB12D prevalence, the number and mean age of females with hemoglobin deficiency, and low ferritin levels was found to be statistically significantly higher in females than males. Conclusions: The prevalence of vitamin D, vitamin B12, folate deficiency and low ferritin levels was found to be high among adolescents. In particular, adolescents admitting with non-specific complaints and for control purposes in big cities must be considered to be at risk for the deficiency of these vitamins and low level of ferritin.

scholarly journals The inflammatory profile of chronic kidney disease patients

2021 ◽  
Vol 5 (3) ◽  
pp. 107-111
Author(s):  
Chaker Hanen ◽  
Jarraya Faiçal ◽  
Toumi Salma ◽  
Kammoun Khawla ◽  
Mahfoudh Hichem ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Renal Failure ◽  
Kidney Disease ◽  
Sedimentation Rate ◽  
Biological Data ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Markers Of Inflammation ◽  
Inflammatory Profile

Background: Chronic kidney disease is a worldwide public health issue which is associated with an increased risk of end-stage renal failure and cardiovascular disease. Systemic inflammation exists during chronic renal failure. Recent researches have highlighted the pivotal role of inflammation between renal and cardiovascular disease. The aim of our study is to determine the inflammatory profile of the patient suffering from chronic kidney disease and the influence of hemodialysis on this profile. Methods: We carried out a cross sectional study on 93 patients in the Nephrology Department at Hedi Chaker University Hospital, Sfax, South of Tunisia. Among those patients, 72 patients underwent hemodialysis and 21 patients had chronic kidney disease at stage 3. Clinical data and antecedents were collected. Biological samples were taken after informing the patients and taking their consent. Biological data consisted in lipid profile, albumin rate, hemoglobin rate, uric acid concentration and the usual markers of inflammation noting sedimentation rate, C - reactive protein and orosomucoid. Results: Hemodialysis group of the 72 patients had mean hemodialysis vintage of 54.6 ± 43 months. The inflammatory profile was worse in hemodialysis patients compared to chronic kidney disease patients. Both sedimentation rate, C - reactive protein and orosomucoid were higher in hemodialysis group than in chronic kidney disease group with 71 ± 35.3 mm vs. 42.1 ± 15.5 mm (p < 0.05); 14.6 ± 28.7 mg/l vs. 6.7 ± 8 mg/l (p = 0.02); 1.3 ± 0.7g/l vs. 0.9 ± 0.4 g/l (p = 0.01), respectively. Conclusion: Inflammation increases in dialysis patient. It deserves the nephrologist’s consideration in order to minimize its harmful effects. The monitoring of inflammation markers must be integrated into the nephrologist’s medical practice.

scholarly journals 019Tilt Table Test Outcome in the Diagnosis and Prevalence of Syncope in Patients with Vitamin D and Vitamin B12 Deficiency

2017 ◽  
Vol 46 (Suppl_3) ◽  
pp. iii13-iii59 ◽  
Author(s):  
Muhammad Ghaznain ◽  
Teresa Mary Donnelly ◽  
Louise Halpenny
Keyword(s):  
Vitamin D ◽  
Vitamin B12 ◽  
Vitamin B12 Deficiency ◽  
B12 Deficiency

scholarly journals Prolonged Hypocalcemia After a Single Dose of Denosumab in Chronic Kidney Disease

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A216-A217
Author(s):  
Akshan Puar ◽  
Zeb Ijaz Saeed
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Alkaline Phosphatase ◽  
Single Dose ◽  
Calcium Carbonate ◽  
Kidney Disease ◽  
Serum Calcium ◽  
Ckd Stage ◽  
25 Hydroxy Vitamin D ◽  
History Of

Abstract Introduction: Denosumab, a monoclonal antibody that inhibits RANK L (receptor activator nuclear factor-kappa beta ligand), is one of the few medications that can be used to treat osteoporosis in patients with chronic kidney disease (CKD). However, its use is associated with a much higher incidence of hypocalcemia in this patient population. What remains unclear is the duration of hypocalcemia after denosumab use. We describe a case of prolonged hypocalcemia of 9 months in a patient with CKD after a single dose of denosumab. Case: A 64-year-old Caucasian man with a history of bilateral lung transplant for interstitial pulmonary fibrosis and CKD Stage IV was referred to the Endocrinology clinic for evaluation of steroid-induced osteoporosis. Bone density scan was consistent with osteoporosis with the lowest T-score of -2.8 at the left femoral neck, which showed a 25.3% decline from a previous one two years prior. His labs upon initial visit: 25 hydroxy Vitamin D: 36.5 ng/mL (30–100), 1, 25 hydroxy vitamin D 32 pg/ml (19.9–79.3), corrected Serum Calcium 8.9 mg/dL (8.5–10.5), Serum Cr 4.38 mg/dL (0.6–1.4), PTH 157 pg/mL (10–65), Serum Alkaline Phosphatase 61 Units/L (25–125), Urine NTX 39 nM BCE/mM creatinine (21–83). After discussing risks and benefits, he was given a dose of subcutaneous denosumab 60 mg. He had been started on Calcium/Vitamin D (600 mg/400 IU BID) prior to receiving his dose. Keeping in mind the increased risk of hypocalcemia given his history of CKD, his corrected serum calcium was checked one week later, and it was 6.5 mg/dL. The patient was asymptomatic. However, given the severity of his hypocalcemia, he was started on calcitriol 0.25 mcg oral BID and calcium carbonate 1200 mg daily. He did show mild improvement in three days to a corrected calcium of 7.0 mg/dL. His calcitriol was briefly increased to 0.5 mcg BID and calcium carbonate was increased to 1800 mg daily. The regimen was weaned to calcitriol 0.25 mcg daily and previous calcium/Vitamin D dosing later that month. Thereafter, his labs were monitored regularly and there were several unsuccessful attempts made to decrease the calcitriol/calcium carbonate. Given persistent hypocalcemia, other bloodwork including a bone specific alkaline phosphatase and celiac screen were checked which were unremarkable. Finally, nine months after his denosumab dose, calcitriol was discontinued safely. Serum calcium levels have remained stable thereafter. Given prolonged hypocalcemia, it was decided not to administer another dose of denosumab. Conclusion: Patients with CKD who receive denosumab are not only at risk for developing severe, but also prolonged hypocalcemia. Therefore, it is imperative to monitor serum calcium levels, not only immediately after receiving a dose, but serially.

Sign in / Sign up

Export Citation Format

Share Document